Recent advances in role of RSK2 in tumorigenesis and its inhibitors
10.3969/j.issn.1000-4718.2025.04.018
- VernacularTitle:RSK2在肿瘤发生发展中作用及其抑制剂的研究进展
- Author:
Haixiao LI
1
;
Yuanbao AI
;
Sen LIU
Author Information
1. 湖北工业大学生命科学与健康工程学院,工业发酵省部共建协同创新中心,发酵工程教育部重点实验室,工业微生物湖北省重点实验室,国家细胞调控与分子药物学科创新引智基地("111计划"),湖北 武汉 430068;湖北微生元生物科技有限公司,湖北 鄂州 436006
- Publication Type:Journal Article
- Keywords:
ribosomal S6 kinase 2;
signalling pathway;
tumor;
inhibitor
- From:
Chinese Journal of Pathophysiology
2025;41(4):775-782
- CountryChina
- Language:Chinese
-
Abstract:
Ribosomal S6 kinase 2(RSK2),an important member of the RSK family,is involved in cell prolifera-tion,transformation,apoptosis,and the cell cycle.It plays a pivotal role in the development and progression of various tu-mors,making it a promising target for anticancer drug development.To date,there is a notable paucity of effective inhibi-tors,with only one compound,PMD-026,having advanced to the clinical stage of testing.Earlier studies have suggested that RSK2 was regulated exclusively by MAPK,however recent research has shown that AKT1 also activates RSK2.This article provides an in-depth review of the structural and functional characteristics of the RSK2 protein,its signal transduc-tion pathways,and the relationship between RSK2 and tumor development and progression.We also reviews the status of current research and the challenges associated with developing inhibitors that target different sites of RSK2.The objective was to provide valuable insights for the advancement of RSK2 inhibitors.
